600276.SS
Jiangsu Hengrui Medicine Co., Ltd. [600276.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600276.SS Stock Summary
Top 10 Correlated Stocks
600276.SS
In the News
600276.SS Financial details
Company Rating
Strong Buy
Market Cap
280.35B
Income
4.21B
Revenue
22.34B
Book val./share
6.23
Cash/share
2.77
Dividend
0.16
Dividend %
0.39%
Employees
20.64K
Optionable
No
Shortable
Yes
Earnings
18 Apr 2024
P/E
60.42
Forward P/E
-
PEG
-85.8
P/S
11.85
P/B
6.41
P/C
15.29
P/FCF
62.45
Quick Ratio
11.4
Current Ratio
12.53
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
0.66
EPS next Y
-
EPS next Q
-
EPS this Y
-14.08%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.96%
Revenue last 5Y
4.08%
Revenue Q/Q
2.98%
EPS Q/Q
5.88%
-
-
-
-
SMA20
-
SMA50
12.5%
SMA100
-6.25%
Inst Own
-
Inst Trans
-
ROA
10%
ROE
11%
ROC
0.11%
Gross Margin
84%
Oper. Margin
20%
Profit Margin
19%
Payout
25%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
35.51-50.5
52W High
-15.3%
52W Low
+21%
RSI
37
Rel Volume
2.02
Avg Volume
29.17M
Volume
59.02M
Perf Week
-7%
Perf Month
-4.96%
Perf Quarter
-0.87%
Perf Half Y
-4.25%
-
-
-
-
Beta
0.219
-
-
Volatility
0.9%, 1.37%
Prev Close
-4.6%
Price
42.35
Change
-4.51%
600276.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.74 | 3.68 | 4.36 | 4.06 | 3.34 | |
| Net income per share | 0.64 | 0.84 | 1 | 0.71 | 0.61 | |
| Operating cash flow per share | 0.44 | 0.6 | 0.54 | 0.66 | 0.2 | |
| Free cash flow per share | 0.35 | 0.51 | 0.45 | 0.4 | -0.11 | |
| Cash per share | 0.64 | 2.14 | 2.59 | 2.93 | 2.81 | |
| Book value per share | 3.1 | 3.91 | 4.8 | 5.49 | 5.94 | |
| Tangible book value per share | 3.07 | 3.88 | 4.79 | 5.46 | 5.69 | |
| Share holders equity per share | 3.1 | 3.91 | 4.8 | 5.49 | 5.94 | |
| Interest debt per share | 0 | 0.07 | 0.25 | 0.18 | 0.21 | |
| Market cap | 195.07B | 385.13B | 590.4B | 323.56B | 245.32B | |
| Enterprise value | 191.18B | 380.5B | 581.2B | 310.08B | 231.57B | |
| P/E ratio | 47.98 | 72.28 | 93.29 | 71.42 | 62.8 | |
| Price to sales ratio | 11.2 | 16.54 | 21.29 | 12.49 | 11.53 | |
| POCF ratio | 70.31 | 100.9 | 172.03 | 76.69 | 193.89 | |
| PFCF ratio | 86.89 | 118.3 | 205.17 | 126.68 | -337.48 | |
| P/B Ratio | 9.89 | 15.54 | 19.35 | 9.24 | 6.49 | |
| PTB ratio | 9.89 | 15.54 | 19.35 | 9.24 | 6.49 | |
| EV to sales | 10.98 | 16.34 | 20.96 | 11.97 | 10.88 | |
| Enterprise value over EBITDA | 38.96 | 57.07 | 78.95 | 61.03 | 48.78 | |
| EV to operating cash flow | 68.91 | 99.69 | 169.35 | 73.5 | 183.02 | |
| EV to free cash flow | 85.15 | 116.88 | 201.97 | 121.4 | -318.57 | |
| Earnings yield | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Free cash flow yield | 0.01 | 0.01 | 0 | 0.01 | 0 | |
| Debt to equity | 0 | 0.02 | 0.05 | 0.03 | 0.04 | |
| Debt to assets | 0 | 0.02 | 0.05 | 0.03 | 0.03 | |
| Net debt to EBITDA | -0.79 | -0.69 | -1.25 | -2.65 | -2.9 | |
| Current ratio | 7.25 | 9.02 | 7.44 | 8.87 | 8.5 | |
| Interest coverage | 962.57 | 893.5 | 1.28K | 990.36 | 633.4 | |
| Income quality | 0.68 | 0.72 | 0.54 | 0.94 | 0.33 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.09 | 0.15 | 0.16 | 0.24 | 0.26 | |
| Sales general and administrative to revenue | 0.06 | 0.07 | 0.08 | 0.08 | 0.08 | |
| Research and developement to revenue | 0.15 | 0.17 | 0.18 | 0.23 | 0.23 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.02 | 0.05 | |
| Capex to operating cash flow | -0.19 | -0.15 | -0.16 | -0.39 | -1.57 | |
| Capex to revenue | -0.03 | -0.02 | -0.02 | -0.06 | -0.09 | |
| Capex to depreciation | -1.39 | -0.91 | -1.24 | -3.2 | -3.45 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Graham number | 6.68 | 8.6 | 10.37 | 9.36 | 9.06 | |
| ROIC | 0.21 | 0.21 | 0.2 | 0.13 | 0.1 | |
| Return on tangible assets | 0.18 | 0.2 | 0.18 | 0.12 | 0.1 | |
| Graham Net | 1.02 | 2.67 | 3.21 | 3.54 | 3.55 | |
| Working capital | 15.58B | 19.84B | 24.28B | 26.79B | 27.29B | |
| Tangible asset value | 19.53B | 24.59B | 30.45B | 34.87B | 36.21B | |
| Net current asset value | 15.51B | 19.69B | 24.11B | 26.49B | 26.99B | |
| Invested capital | 0 | 0.02 | 0.05 | 0.03 | 0.04 | |
| Average receivables | 5.39B | 6.47B | 8.15B | 8.95B | 9.24B | |
| Average payables | 1.07B | 1.35B | 1.36B | 1.84B | 2.01B | |
| Average inventory | 910.15M | 1.32B | 1.69B | 2.09B | 2.43B | |
| Days sales outstanding | 126.03 | 108.46 | 123.56 | 119.97 | 170.85 | |
| Days payables outstanding | 219.21 | 161.55 | 156.16 | 219.75 | 185.04 | |
| Days of inventory on hand | 161.13 | 201.34 | 193.8 | 234.37 | 256.54 | |
| Receivables turnover | 2.9 | 3.37 | 2.95 | 3.04 | 2.14 | |
| Payables turnover | 1.67 | 2.26 | 2.34 | 1.66 | 1.97 | |
| Inventory turnover | 2.27 | 1.81 | 1.88 | 1.56 | 1.42 | |
| ROE | 0.21 | 0.22 | 0.21 | 0.13 | 0.1 | |
| Capex per share | -0.08 | -0.09 | -0.09 | -0.26 | -0.31 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.92 | 0.84 | 0.86 | 0.89 | 0.92 | |
| Net income per share | 0.17 | 0.12 | 0.19 | 0.17 | 0.18 | |
| Operating cash flow per share | 0.17 | 0.12 | 0.19 | 0.42 | 0.23 | |
| Free cash flow per share | 0.16 | 0.04 | 0.13 | 0.32 | 0.16 | |
| Cash per share | 2.91 | 2.81 | 2.51 | 2.67 | 2.77 | |
| Book value per share | 5.93 | 5.94 | 6.11 | 6.11 | 6.23 | |
| Tangible book value per share | 5.72 | 5.69 | 5.81 | 5.74 | 5.83 | |
| Share holders equity per share | 5.93 | 5.94 | 6.11 | 6.11 | 6.23 | |
| Interest debt per share | 0.06 | 0.21 | 0.01 | 0.01 | 0.01 | |
| Market cap | 217.48B | 245.32B | 272.64B | 304.58B | 285.75B | |
| Enterprise value | 201.62B | 231.57B | 258.5B | 288.52B | 268.44B | |
| P/E ratio | 51.58 | 83.68 | 55.01 | 71.22 | 61.29 | |
| Price to sales ratio | 38.04 | 46.03 | 49.64 | 53.66 | 48.89 | |
| POCF ratio | 206.32 | 334.72 | 220.03 | 114.44 | 199.34 | |
| PFCF ratio | 217.78 | 890.93 | 319.12 | 147.79 | 272.58 | |
| P/B Ratio | 5.92 | 6.49 | 7.01 | 7.84 | 7.21 | |
| PTB ratio | 5.92 | 6.49 | 7.01 | 7.84 | 7.21 | |
| EV to sales | 35.27 | 43.45 | 47.06 | 50.83 | 45.92 | |
| Enterprise value over EBITDA | 171.43 | 377.53 | 195.11 | 239.51 | 201.14 | |
| EV to operating cash flow | 191.28 | 315.96 | 208.61 | 108.41 | 187.26 | |
| EV to free cash flow | 201.91 | 840.99 | 302.57 | 140 | 256.06 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0.01 | 0 | |
| Debt to equity | 0.01 | 0.04 | 0 | 0 | 0 | |
| Debt to assets | 0.01 | 0.03 | 0 | 0 | 0 | |
| Net debt to EBITDA | -13.48 | -22.42 | -10.67 | -13.32 | -12.97 | |
| Current ratio | 11.47 | 8.5 | 12.08 | 13.23 | 12.53 | |
| Interest coverage | -3.51K | 103.74 | 1.36K | 453.9 | 1.3K | |
| Income quality | 1 | 1 | 1 | 2.49 | 1.23 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.95 | 0.02 | 0 | 0.92 | 0.03 | |
| Sales general and administrative to revenue | 0.16 | 0.05 | 0.1 | 0.02 | 0.17 | |
| Research and developement to revenue | 0.23 | 0.26 | 0.21 | 0.21 | 0.24 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | |
| Capex to operating cash flow | -0.05 | -0.62 | -0.31 | -0.23 | -0.27 | |
| Capex to revenue | -0.01 | -0.09 | -0.07 | -0.11 | -0.07 | |
| Capex to depreciation | -0.34 | -2.77 | -2.2 | -3.44 | 1.27 | |
| Stock based compensation to revenue | 0 | 0.01 | 0 | 0.02 | -0.02 | |
| Graham number | 4.77 | 3.92 | 5.17 | 4.81 | 5.07 | |
| ROIC | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | |
| Return on tangible assets | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | |
| Graham Net | 3.75 | 3.55 | 3.63 | 3.62 | 3.76 | |
| Working capital | 27.03B | 27.29B | 28.11B | 27.63B | 28.18B | |
| Tangible asset value | 35.46B | 36.21B | 37B | 36.51B | 37.08B | |
| Net current asset value | 26.75B | 26.99B | 27.83B | 27.37B | 27.96B | |
| Invested capital | 0.01 | 0.04 | 0 | 0 | 0 | |
| Average receivables | 9.41B | 9.57B | 10.78B | 10.73B | 10.06B | |
| Average payables | 1.66B | 1.74B | 1.83B | 1.67B | 1.56B | |
| Average inventory | 2.35B | 2.38B | 2.5B | 2.48B | 2.45B | |
| Days sales outstanding | 144.43 | 168.15 | 190.23 | 156.22 | 158.1 | |
| Days payables outstanding | 157.27 | 194.5 | 197.24 | 143.93 | 168.68 | |
| Days of inventory on hand | 211.49 | 269.66 | 266.25 | 238.62 | 251.19 | |
| Receivables turnover | 0.62 | 0.54 | 0.47 | 0.58 | 0.57 | |
| Payables turnover | 0.57 | 0.46 | 0.46 | 0.63 | 0.53 | |
| Inventory turnover | 0.43 | 0.33 | 0.34 | 0.38 | 0.36 | |
| ROE | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | |
| Capex per share | -0.01 | -0.07 | -0.06 | -0.09 | -0.06 |
600276.SS Frequently Asked Questions
What is Jiangsu Hengrui Medicine Co., Ltd. stock symbol ?
Jiangsu Hengrui Medicine Co., Ltd. is a CN stock and trading under the symbol 600276.SS
What is Jiangsu Hengrui Medicine Co., Ltd. stock quote today ?
Jiangsu Hengrui Medicine Co., Ltd. stock price is $42.35 today.
Is Jiangsu Hengrui Medicine Co., Ltd. stock public?
Yes, Jiangsu Hengrui Medicine Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 29.17M
- Market Capitalization 280.35B
- Employee 20.64K
- CEO Mr. Hong Bin Dai
- Headquarters Lianyungang,CN
- IPO Date 2000-10-18
-
Website
https://www.hrs.com.cn 
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
